Hepatitis A Vaccine (Inactivated Viral)
HAVRIX® 1440 Supplier: GlaxoSmithKline Inc.
HAVRIX® 720 Junior Supplier: GlaxoSmithKline Inc.
(Adult presentation: 1440 ELU/1.0 mL; Pediatric presentation: 720 ELU/0.5 mL)

INDICATIONS:
- See Hepatitis A Vaccine Indications

DOSES AND SCHEDULE: A, B
Routine Aboriginal infant series: C, D 2 doses given as 0.5 mL of HAVRIX® 720 Junior (720 ELU) IM at 6 and 18 months of age.

Other eligible individuals:

6 months-18 years of age (inclusive): D 2 doses given as 0.5 mL of HAVRIX® 720 Junior (720 ELU) IM, separated by 6 months.

19 years of age and older: D 2 doses given as 1.0 mL of HAVRIX® 1440 (1440 ELU) IM, separated by 6 months.

ADMINISTRATION:
No additional requirements.

BOOSTER DOSES:
No booster doses are recommended at this time.

SEROLOGICAL TESTING:
Serological testing may be indicated prior to immunization for select populations, see Part 2 – Immunization of Special Populations. Post-vaccination serological testing is not indicated following a hepatitis A vaccine series.

CONTRAINDICATIONS:
1. History of an anaphylactic reaction to a previous dose of any hepatitis A vaccine, or to any component of HAVRIX® 1440 or HAVRIX® 720 Junior.

A Hepatitis A vaccines may be used interchangeably using the age-appropriate dose for the product being given.
B HAVRIX® 720 Junior is approved for use in children 1-18 years of age (inclusive). However, NACI indicates that hepatitis A vaccine may be provided, beginning at 6 months of age, to infants who are at increased risk of infection or severe hepatitis A.
C Aboriginal children remain eligible for hepatitis A vaccine up to and including 18 years of age using the age-appropriate dosing and schedule.
D For HIV positive individuals, provide 3 doses of vaccine at 0, 1 and 6 months.
Hepatitis A Vaccine (Inactivated Viral)
HAVRIX® 1440  Supplier: GlaxoSmithKline Inc.
HAVRIX® 720 Junior  Supplier: GlaxoSmithKline Inc.

PRODUCT COMPONENTS:
Potential allergens: neomycin sulphate, bovine serum albumin.
Other components: formaldehyde, aluminum hydroxide, potassium chloride, disodium phosphate, monopotassium phosphate, polysorbate 20, amino acids.

PRECAUTIONS:
Not applicable.

SPECIAL CONSIDERATIONS:
• For more information related to pre-exposure prophylaxis against hepatitis A related to travel, refer clients to their local travel clinic.
• In order to address the gaps in age approvals for hepatitis A vaccines in Canada, a 0.5 mL dose of HAVRIX® 1440 can be used for adolescents 16-18 years of age (inclusive), if required.

ADVERSE EVENTS:
Local: soreness, redness.
Systemic: headache, fatigue, fever, malaise, nausea, vomiting, diarrhea.